-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $6

Benzinga·06/17/2025 15:08:45
Listen to the news
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $10 to $6.